Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Theophylline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 9/20 | 0.96 |
| ▸ | PDE4B known ✓ | Q07343 | 9/20 | 0.96 |
| ▸ | PDE4C known ✓ | Q08493 | 9/20 | 0.96 |
| ▸ | PDE4D known ✓ | Q08499 | 9/20 | 0.96 |
| ▸ | ADORA2A known ✓ | P29274 | 8/20 | 0.96 |
| ▸ | ADORA2B known ✓ | P29275 | 8/20 | 0.96 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.96 |
| ▸ | ADORA1 known ✓ | P30542 | 2/20 | 0.96 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.62 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.62 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.96 |
| ▸ | ALPL | P05186 | 1/20 | 0.96 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.84 |
| ▸ | CFTR | P13569 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theophylline Anhydrous SCHEMBL8595167 | 1.00 | ATAD2 (1.00) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL3051675 | 1.00 | ATAD2 (1.00) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL25398274 | 1.00 | ATAD2 (1.00) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL11459710 | 0.98 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL1400606 | 0.98 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL1173080 | 0.98 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL5454758 | 0.98 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL8375983 | 0.98 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL21753826 | 0.98 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D | |
| Theophylline Anhydrous SCHEMBL1274777 | 0.98 | ATAD2 (0.96) | ATAD2PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 185040 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144923-A1 | EXTRACORPOREAL BLOOD TREATMENT APPARATUS | GAMBRO LUNDIA AB (SE) | 2026-05-28 | — | — | US | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4243925-B1 | APPARATUS FOR DELIVERING ENHANCED STIMULATION WAVEFORMS | NALU MEDICAL INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4746991-A2 | CO-N2 SEPARATION IN A SIMULATED MOVING BED | Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek TNO (NL) | 2026-05-27 | — | — | EP | claimed |
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| US-12639496-B2 | Scalable, optimal retiming of multi-clocked netlists | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2026-05-26 | — | — | US | claimed |
| CN-122092300-A | Peak regulation auxiliary-oriented cement industrial park optimal scheduling method and system | — | 2026-05-26 | — | — | CN | claimed |
| US-4002756-A | Useful pro-drug forms of theophylline | INTERX RESEARCH CORPORATION (US) | 1977-01-11 | — | — | US | claimed |
| US-4000132-A | REACTION WITH CARBOXYLIC ACID, PHOSGENE, OR THIONYL CHLORIDE | INTERX RESEARCH CORPORATION (US) | 1976-12-28 | — | — | US | claimed |
| US-3978213-A | SOFTENING SKIN | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-08-31 | — | — | US | claimed |
| US-3965256-A | ALCOHOL AND HYDRATED HYDROXYALKYL CELLULOSE | SYNERGISTICS (US) | 1976-06-22 | — | — | US | claimed |
| US-3965255-A | DRUG ENCAPSULATED IN OR COATED WITH A SOLVENT MEMBRANE | E. E. ELJIM ECOLOGY LTD. (IL) | 1976-06-22 | — | — | US | claimed |
| US-3957994-A | THEOPHYLLINE, 2-PYRROLIDONE, N-LOWER ALKYL-2-PYRROLIDONE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-05-18 | — | — | US | claimed |
| US-3957995-A | ADMINISTERING, CEREBRAL VASODILATOR ACTIVITY | PARCOR (FR) | 1976-05-18 | — | — | US | claimed |
| US-3954663-A | EXTRACTION, XANTHINE DERIVATIVES | TEIKOKU HORININE MFG. CO. LTD. (JA) | 1976-05-04 | — | — | US | claimed |
| US-3939089-A | PEROXYSULFATE | TOKAI DENKA KOGYO KABUSHIKI KAISHA (JA) | 1976-02-17 | — | — | US | claimed |
| US-3935196-A | Useful pro-drug forms of theophylline | INTERX RESEARCH CORPORATION (US) | 1976-01-27 | — | — | US | claimed |